Skip to main content

Professor Chris Probert
MD FRCP FHEA

Contact

Chris.Probert@liverpool.ac.uk

+44 (0)151 795 4010

Research

Metabolomics

Recently, most of my research has be directed towards volatile organic compounds and their use as biomarkers of IBS, IBD and various cancers.

The intestinal microbiome and mycobiome

My group also looks at the microbiome and mycobiome of the intestine in humans, mice and equines.

Clinical interests

I have an ongoing-interest in IBD and IBS.

Research grants

Mechanisms Affecting the Gut of Preterm Infants in Enteral feeding trials (MAGPIE)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

February 2016 - September 2019

VOID-bladder cancer

CANCER RESEARCH UK (UK)

January 2017 - April 2019

IASO: A phase II randomised placebo controlled double blind trial of Interleukin 1 blockade in Acute Severe Colitis

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

March 2017 - October 2022

Characterization of the gut mycobiome in an inception cohort of paediatric inflammatory bowel disease patients

GUTS (UK CHARITY)

April 2018 - March 2019

Understanding the mechanisms for the variation in beneficial effects of dietary fibre in IBS: an old concept in new light

DEPARTMENT FOR BUSINESS, ENERGY AND INDUSTRIAL STRATEGY (BEIS) (UK)

August 2016 - January 2021

MECNUT: Impact of dietary exposure to emulsifiers on the intestinal mucosa - implications for inflammatory bowel disease and metabolic syndrome

MEDICAL RESEARCH COUNCIL

November 2017 - September 2021

Volatile Organic compounds for the DEtection of Colorectal cAncer: VODECA

CANCER RESEARCH UK (UK)

November 2018 - July 2023

Investigation of octen-3-ol, a fungal metabolite, in faeces of people with Parkinson’s disease

WELLCOME TRUST (UK)

July 2015 - August 2015

Study to determine the effect of ferric maltol on gut microbiota in inflammatory bowel disease patients with iron deficiency

SHIELD THERAPEUTICS PLC (UK)

January 2018 - January 2019

Peripheral blood gene expression profiling as predictors of response to biological therapy in ulcerative colitis

CROHN'S AND COLITIS UK (UK)

September 2016 - October 2021

Diarrhoea Diagnostic Device: From Bench to Bedside

WELLCOME TRUST (UK)

October 2014 - December 2015

Impact Acceleration Account - University of Liverpool 2012

ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL

October 2012 - March 2017

Examination of the fungal microbiome in Crohn’s disease and an investigation of the impact of fungi on bacterial microbiota and their interaction with phagocytic leucocytes

NAT ASSOC FOR COLITIS & CROHNS DISEASE (UK)

September 2015 - August 2017

Evaluation of faecal volatile organic compounds in the diagnosis of paediatric inflammatory bowel disease

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

April 2017 - September 2020

The role of faecal and urinary Volatile Organic Compounds (VOCs) as a non-invasive diagnostic biomarker of colorectal cancer

SHIRE PHARMACEUTICALS LIMITED (UK)

May 2015 - April 2017

The role of urinary volatile organic compounds as a biomarker for hepatocellular carcinoma

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

August 2015 - July 2016

Can Volatile Organic Compounds be used to detect Campylobacter infection in Poultry Houses?

ROBOSCIENTIFIC LIMITED (UK)

October 2012 - March 2013

Systems medicine of chronic inflammatory bowel disease (SysmedIBD)

EUROPEAN COMMISSION

December 2012 - November 2017

Faecal Microbiota in Preterm Infants Developing Necrotising Enterocolitis (NEC) - The DOVEtail Study.

ACTION MEDICAL RESEARCH (UK), BIRMINGHAM CHILDREN'S HOSPITAL (UK)

September 2012 - October 2015

The role of faecal Volatile Organic Compounds (VOCs) as a non-invasive diagnostic biomarker of colorectal cancer (pilot study)

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

January 2014 - June 2015

Influence of iron supplementation on gut flora and the natural history of Inflammatory Bowel Disease

LIBYAN EMBASSY IN LONDON🚩

April 2013 - March 2015

Analysis of volatile organic compounds (VOCs) emitted from the faeces of preterm infants as a predictor of preclinical necrotising enterocolitis (NEC).

ACTION MEDICAL RESEARCH (UK)

October 2012 - February 2016

Trial of antibiotics and hydroxychloroquine in Crohn's disease

NAT ASSOC FOR COLITIS & CROHNS DISEASE (UK)

October 2013 - March 2020